239 results about "Low Grade Malignant Neoplasm" patented technology

KLRB1 binding agents (in particular anti-KLRB1 antibodies and antigen binding portion thereof) and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, INKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.

The invention relates to the technical field of biomedicine, in particular to a hepatic cell differentiation degree evaluation method based on multi-omics data, which comprises the steps of sample collection and preprocessing, transcriptomics, proteomics and metabonomics data analysis, multi-omics data integration and modeling and result output. By integrating multi-level biological information, a multi-dimensional scoring model is constructed, the liver cell differentiation state is quantitatively evaluated, and a standardized grading system is provided for clinic. The method can solve the limitation of single omics analysis, improves the evaluation accuracy and reliability, has universality, can be popularized to other malignant tumor research, and assists precise medical development.

Treatment of damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) is provided by delivering specialized pulsed electric field energy to target tissue areas in a specific dose so as to obtain a superior outcome. The specialized PEF energy and delivery has been optimized to provide advanced treatment of target tissue areas, including destruction of undesired tissue and generation of improved inflammatory and immune responses. The specialized PEF energy provides superior outcomes to radiofrequency ablation and irreversible electroporation.

The invention discloses a malignant tumor AI auxiliary diagnosis system based on an internet hospital, relates to the technical field of medical informatization and artificial intelligence, and improves the diagnosis and treatment efficiency through individualized early warning and closed-loop intervention. And closed-loop management from early warning to intervention is realized through the doctor-patient interaction module. When high-risk early warning occurs, the system immediately notifies a doctor and a patient to take actions, so that the time link from problem discovery to problem processing is shortened.

Provided are a T-cell receptor (TCR) and the use thereof, wherein the TCR contains an α chain containing a variable region and / or a β chain containing a variable region. The TCR is capable of specifically recognizing an A1101-restricted KRASG12V mutation and an A1101-restricted KRASG12D mutation. A T cell transducing the TCR (TCR-T) can bind to an antigen short peptide-HLA-A1101 complex, and can be used for treating malignant tumors carrying the KRASG12V mutation and KRASG12D mutation.

KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.

The invention discloses a digestive tract malignant tumor metastasis risk assessment method and system based on artificial intelligence, and relates to the field of digestive tract malignant tumor metastasis risk assessment. The method comprises the following steps: firstly, acquiring PET-CT three-dimensional image data of a colorectal cancer patient, and constructing and extracting a three-dimensional voxel matrix of a liver region according to the PET-CT three-dimensional image data; inputting the voxel matrix of the liver region into a pre-trained convolutional neural network model, and outputting a probability distribution matrix of each voxel; setting a basic confidence threshold of the malignant tumor metastasis, and extracting candidate focuses according to the probability distribution matrix and the confidence threshold of the malignant tumor metastasis; obtaining the maximum diameter of the candidate focus, dynamically and adaptively adjusting the confidence coefficient threshold value of the malignant tumor metastasis focus according to the maximum diameter, and generating a binary mask matrix; calculating a comprehensive risk score of colorectal cancer liver metastasis according to the binary mask matrix and grading; according to the invention, the false positive inhibition capability can be enhanced and the risk assessment accuracy can be improved.

The invention relates to a layered prediction method and system for the risk of malignant tumors related to dermatomyositis. The method comprises the following steps: collecting clinical index data of a patient suffering from dermatomyositis, the clinical index data comprising an anti-TIF1-gamma antibody detection result, an interstitial lung disease existence state, a dermatomyosis existence state, an anemia state and a dermatomyositis type; constructing a comprehensive scoring model to generate a risk stratification prediction result according to the clinical index data; the comprehensive scoring model is used for performing binary assignment on each index to obtain a score of a corresponding item; calculating the sum of scores of all indexes of the patient to obtain a total risk score; and layering the risk of the malignant tumor accompanied by the patient based on the total risk score, and outputting a risk layering result. According to the method, the cancer risk of the patient with dermatomyositis can be effectively predicted, and the reliability, convenience and practicability of layered prediction of the cancer risk are improved.

Provided is a method of treating malignant tumor by an azabicyclic compound, particularly, with eye disorder reduced. The present invention provides a method for treating malignant tumor, comprising administering an effective amount of 3-ethyl-4-[3-(1-methylethyl)-4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-1H-pyrazolo[3,4-b]pyridin-1-yl]benzamide (compound 1) or a salt thereof to a patient in need thereof according to a dosing regimen, wherein the dosing regimen comprises administering the compound 1 or the salt thereof at a dose from 40 mg / body / day to 240 mg / body / day in terms of the amount of the compound 1 for consecutive days, and then providing a withdrawal period of at least 2 days.

Methods for prognosticating if an individual afflicted with a malignant tumor is likely to respond favorably to immunotherapy comprising testing for the presence or absence of DARC expression in the tumor, and if no DARC expression is detected, identifying the individual as not being suitable for immunotherapy, and optionally administering an anti-cancer therapy other than immunotherapy to the individual, or if DARC expression is detected, then identifying the individual as being suitable for immunotherapy, and optionally administering immunotherapy or any other anti-cancer therapy to the individual.

Therapeutic compositions comprising chitosan-derived compositions are useful agents when administered in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.

The invention discloses a gallbladder malignant tumor protein diagnosis biomarker combination, a kit and application. The protein marker provided by the invention comprises CA1 and / or IGFBP6 (insulin-like growth factor binding protein 6). According to the invention, an LC-MS / MS mass spectrometry method is adopted, mass spectrometry is carried out on a large number of clinical plasma samples, and by calculating log2 difference multiples of corresponding protein molecule contents in the plasma of a gallbladder cancer patient and the plasma of a normal person, it is determined that two protein molecules (CA1 protein and IGFBP6 protein) have good inspection benefits; the kit can be used as a marker for early diagnosis of gallbladder cancer; therefore, the invention provides a non-invasive screening means based on plasma, and the non-invasive screening means is used for predicting the cholecystic malignant tumor and distinguishing the cholecystic carcinoma crowd from the non-cancer crowd. And materials are convenient to take, the blood sample amount is small, and the sensitivity is high. The invention can fill the blank that no protein marker combination with high diagnostic efficiency exists at present for the cholecystic malignant tumor, and has great clinical significance.

HPV16 is a main cause of malignant tumors such as cervical cancer, and E6 protein of HPV16 becomes a key treatment and diagnosis target. In the prior art, an HPV16 detection antibody has the problems of poor stability, dependence on cold chain transportation, low preparation efficiency and the like. According to the invention, a nano antibody sequence which is high in affinity (dissociation constant KD is less than or equal to 1 * 10 <-7 > M) and stable at room temperature is obtained through total synthesis library construction and a phage-assisted directed evolution (PACE) screening technology. After the antibody is stored at 25 DEG C for 30 days, the activity of the antibody is kept to be greater than or equal to 95%, the antibody can be directly used for household test paper, the accuracy rate reaches 98%, and meanwhile, the antibody can be expanded to medical applications such as CAR-T cell therapy. Compared with a traditional antibody, the antibody has the advantages of being short in preparation period, low in cost, wide in application scene and the like, and a breakthrough solution is provided for early screening of cervical cancer.

The application relates to the field of biological preparations, and particularly discloses an immunochromatographic reagent for detecting malignant tumors in urine and application thereof, which is used for solving the problems of poor recognition of tumor specific epitopes, heavy background interference, spectrum overlap and high subjectivity of artificial judgment in the single staining and color development of acridine orange in the detection of urinary exfoliative cells of bladder cancer. The color development reagent comprises A reagent, B reagent, C reagent and D reagent. The A reagent is provided with an antibody complex for target antigens of bladder tumor cells in urine exfoliation and acridine orange. The B reagent comprises a fluorescently labeled secondary antibody composition corresponding to the A reagent and an enzyme-labeled secondary antibody-tyramide deposition amplification composition. In the application, AI imaging analysis is adopted to calibrate layered recognition labels and acridine orange staining negative and positive labels. Through multi-target immunochromatography, two sets of color separation amplification schemes and AI imaging analysis, the application improves the recognition ability of bladder tumor specific epitopes, the image quality and the image analysis accuracy in the detection of urinary exfoliative cells.

This invention discloses a composite nanodelivery system encapsulated in a fusion membrane, its preparation method, and its applications. The nanodelivery system comprises a Ti3C2 / TiO2 / CuInS2 composite material, oxaliplatin loaded thereon, and a fusion membrane encapsulating the outer layer; the fusion membrane is formed by the fusion of Fusobacterium nucleatum extravesicles and M1 macrophage membranes. This invention also discloses a method for preparing the nanodelivery system, including the steps of preparing the Ti3C2 / TiO2 / CuInS2 composite material, preparing the fusion membrane, loading oxaliplatin, and encapsulating it in the fusion membrane. The nanodelivery system prepared by this invention exhibits pH-responsive drug release characteristics, generating H2S in the tumor microenvironment and H2 under light irradiation, while also possessing photocatalytic activity. This invention combines chemotherapy, photoelectrocatalytic therapy, and the regulation of multiple active substances, and can be used to prepare drugs for treating malignant tumors of the digestive system.

This invention provides the application of Jiawei Xihuang Pill (MXHP) in the preparation of drugs for the prevention and / or treatment of malignant tumors. This invention also provides the application of Jiawei Xihuang Pill in combination with chemotherapy drugs for the prevention and / or treatment of malignant tumors, particularly glioblastoma multiforme (GBM), wherein the active ingredients of Jiawei Xihuang Pill are prepared from bezoar, musk, vinegar-processed frankincense, vinegar-processed myrrh, and Panax notoginseng root extract in a weight ratio of 14-16:14-16:545-555:545-555:245-255. MXHP can synergistically inhibit the growth of glioblastoma in situ and induce tumor cell apoptosis, indicating that MXHP may be a potential therapeutic drug. Furthermore, compared to XHP, MXHP significantly prolongs the median survival of GBM, exhibiting an enhanced anti-GBM effect.

The invention belongs to the field of molecular biology, particularly relates to the field of tumor treatment, and particularly relates to application of a TRK inhibitor LYS-8 in preparation of a medicine for treating malignant tumors, particularly pancreatic cancer. LYS-8 is a small molecule TRK inhibitor with a novel structure, and research finds that LYS-8 can significantly inhibit TRK kinase activity and down-regulate downstream PI3K-AKT and other signal channels. Experimental results show that the inhibition effect of LYS-8 in pancreatic cancer cells is obviously superior to that of colorectal cancer cells, and the IC50 value of LYS-8 is lower; in an animal model, the tumor inhibition rate of LYS-8 on pancreatic cancer reaches about 70%, and the inhibition rate on colorectal cancer is about 56%, which is obviously superior to that of a colorectal cancer model. The invention reveals that LYS-8 has an unexpected curative effect advantage on pancreatic cancer, and a new drug choice is provided for targeted therapy of pancreatic cancer.

The present disclosure describes the use of an anti-insulin receptor antibody to treat neoplasms and / or tumor-associated hyperinsulinism and resulting hypoglycemia caused by benign or malignant neoplastic production of insulin and / or other effector substances (e.g., IGF-2 or its variants) that interact with the INSR and thus result in insulin-like action.

The invention discloses a macrophage-targeting lipid nanoparticle and application thereof in malignant tumor treatment, ID3 mRNA is delivered through the lipid nanoparticle, firstly, an ID3 sequence is subjected to codon optimization to improve the expression efficiency and stability of ID3 protein, and the core treatment effect is enhanced; the lipid composition and the targeting ligand of the nanoparticles are further optimized, and mannose modified PEG lipid material (DSPE-PEG2000-Mannose) is specifically combined with the CD206 receptor on the surface of the macrophage, so that the targeting property and the transfection efficiency of the delivery system are remarkably improved. The ID3 mRNA is delivered to the macrophages by utilizing the lipid nanoparticles of the targeted macrophages, so that the tumor cells can be effectively swallowed and killed, the in-situ treatment of pancreatic cancer is realized, and better tumor inhibition and immune activation effects are achieved.

The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.

A method for determining whether a subject is at risk for having a progressing or high-grade pre-invasive lesion, nodule or small mass, or having a solid malignant tumour is described the method comprising: (i) determining a ratio of activated and / or exhausted T cells:naive and / or resting T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, or (ii) determining a ratio of activated and / or exhausted T cells:T cells which are not activated and / or exhausted T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, (iii) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising Ki67 and CD39, and / or (iv) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the T cells are CD4 T cells, and wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising FoxP3.

The invention relates to a medical instrument for gynecologic operation, in particular to a uterus traction device capable of avoiding tumor cell diffusion and a using method thereof.The traction device comprises a bag, the bag is provided with a closed end used for wrapping the bottom of the uterus and an open end used for facing the cervix uteri opening, and the bag is provided with an opening. The open end is provided with an adjusting and tightening mechanism, the cervix uteri, the uterus body and the double accessories of the cervix uteri and the uterus body can be wrapped in the bag by pulling the open end, and then the open end is tightened through the adjusting and tightening mechanism. A wrapping path in the direction from the bottom of the uterus to the cervix uteri opening is adopted, it is ensured that the uterus and contents of the uterus are completely wrapped and isolated in the bag by tightening the opening end, the operation concept that isolation is carried out in advance is achieved, the operation view is protected in the whole process, and tumor-free traction in the operation process is facilitated; in addition, the risks of incision planting and abdominal cavity spreading in malignant tumor surgery can be greatly reduced, the possibility of tumor cell spreading is avoided, and iatrogenic injury is reduced.

To provide a therapeutic agent enabling treatment of a malignant tumor.SOLUTION: A therapeutic agent comprising a substance that recognizes a target expressed in an erythroblast, where the therapeutic agent is administered such that, during a dosing period, a serum concentration of the substance in a subject administered with the therapeutic agent is maintained at 10% or more of a maximum value after administration.SELECTED DRAWING: None

Disclosed in the present invention are nitrogen-containing compounds as well as a preparation method therefor and the use thereof. Specifically disclosed in the present invention are compounds shown as formula I or pharmaceutically acceptable salts thereof, which have one or more of the following advantages: accurate targeting of tumor cells, long tumor retention and inhibition time, and capability of being safely used for malignant tumor diagnosis, staging and / or treatment.

The present invention belongs to the technical field of medicine, and specifically relates to the use of a compound as represented by the following formula (I) or a pharmaceutically acceptable salt, isomer, or crystal form thereof in the preparation of a drug for preventing or treating malignant B cell tumors.

This provides an improved method for treating malignant tumors in human patients. [Solution] A method comprising administering a therapeutically effective dose of a LAG-3 inhibitor; a PD-1 pathway inhibitor; and an immunotherapy agent.

Provided are methods and compositions for treating solid tumors in patients carrying an IDH1 and / or IDH2 mutation using a combination of a dual inhibitor of a mutant IDH1 or IDH2 enzyme and a DNA demethylating agent.

This invention discloses a methylation marker for the differential diagnosis of malignant and benign breast tumors. The invention provides the application of the methylated SH3PXD2B gene as a marker in product preparation; the product is used for at least one of the following purposes: (1) distinguishing between benign and malignant breast tumors; (2) distinguishing between benign breast tumors and different subtypes or stages of malignant breast tumors; (3) distinguishing between different subtypes or stages of malignant breast tumors. This invention has significant scientific and clinical application value for differentiating between benign and malignant breast tumors, different subtypes or stages of malignant breast tumors, and guiding the development of reasonable clinical treatment plans.

The invention discloses a 2-amino-4-anilino pyrimidine compound as well as a preparation method and application of the 2-amino-4-anilino pyrimidine compound. The compound has a strong inhibition effect on EGFR (epidermal growth factor receptor) gene mutation targets and c-MET and has a strong inhibition effect on osimertinib drug-resistant cells; and the compound can inhibit proliferation of various tumor cells, and provides excellent application prospects for treatment of EGFR gene mutation and MET amplified malignant tumors.